Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Towards medical treatments using cell level control

01.11.2012
Researchers at Tokyo Institute of Technology and the Weizmann Institute of Science identify a means of controlling biological processes that could help treatments for immune disease, neurological disorders and cancer.
Researchers at Tokyo Institute of Technology and the Weizmann Institute of Science identify a means of controlling biological processes that could help treatments for immune disease, neurological disorders and cancer.

The cellular response to a number of signals including inflammatory cytokines, tumor promoters, carcinogens, and chemotherapeutic agents hinge on the transcription factor NF-êB. Rivka Dikstein and colleagues at Tokyo Institute of Technology in Japan and the Weizmann Institute of Science in Israel identify how the protein DSIF controls NF-êB activity. The research may lead to methods for controlling inflammation, and immune responses, as well as the cell cycle processes that can lead to cancer.
Activity of NF-êB is usually transient because some of the gene products function as negative regulators of NF-êB, resulting in a negative feedback loop (Figure 1). This is desirable because persistent activation of NF-êB can lead to various pathogenic conditions such as chronic inflammation, autoimmune diseases, and cancer.

Dikstein and colleagues treated cells to reduce the expression of DSIF and monitored the effect on protein levels of NF-êB’s target genes. They found that in the treated ‘DSIF knockdown’ cells the levels of these proteins failed to recover following a degradation process. Further investigation revealed that DSIF plays an integral role in the maturation and transport of messenger RNAs (Figure 2).

“The unique control of the negative feedback regulator genes by DSIF may be utilized by cells under circumstances in which prolonged NF-êB activity is needed,” explain the authors. Their future studies will focus on DSIF under specific settings with a view to identifying drug targets for selective manipulation of NF-êB activity.

BACKGROUND

NF-êB induces gene expression responsible for a number of biological processes including inflammation and cell survival. Its deregulation is linked to chronic inflammation and cancer but so far the mechanisms behind these processes have not been fully understood.

Nuclear transport is integral to NF-êB activity. In unstimulated cells it is retained inactive in the cytoplasm. Signals that trigger its activation result in its transport into the nucleus where it activates responsive genes, such as A20 and IêBá.

Figure 1. Negative feedback regulation of inflammatory responses. The transcription factor NF-êB activates transcription of its target genes, such as A20 and IêBá. Products of these genes function as negative regulators of NF-êB and limit the duration of its activation. This is desirable because persistent activation of NF-êB can lead to various pathogenic conditions such as chronic inflammation, autoimmune diseases, and cancer.


Figure 2. The role of DSIF in the control of inflammatory responses. Upon NF-êB activation, DSIF is recruited to the A20 and IêBá genes and contributes to the negative feedback regulation in a unique manner. DSIF facilitates the expression of these genes by stimulating capping, splicing, and export of their mRNAs. Otherwise, these steps are rate-limiting, and A20 and IêBá proteins are not synthesized successfully.

Activity of NF-êB is usually transient because products of these genes function as negative regulators of NF-êB, resulting in a negative feedback and limiting the duration of NF-êB activation (Figure 1). In certain diseases NF-êB activation becomes persistent, perhaps due to an interruption of this feedback loop.

NF-êB activation results in recruitment of the protein DSIF at the target genes A20 and IêBá. The researchers confirmed the role of DSIF in the negative feedback regulation of NF-êB activity by downregulating a protein subunit of DSIF and comparing the treated cells with controls. In untreated cells the levels of proteins for the target genes A20 and IêBá are high. Although the levels diminish significantly in 30 minutes following a process called TNF-á induction, which is caused by degradation of the proteins, within 2 hours the levels recover. In knockdown cells, however, the levels remained diminished 2 hours after TNF-á induction.

Further investigations using chromatin immunoprecipitation assays revealed abnormalities in the synthesis of A20 and IêBá proteins in the knock down cells. A significant portion of the A20 and IêBá mRNAs in the knockdown cells were uncapped and unspliced (Fig. 2).

The researchers also studied how export was affected in DSIF knockdown cells. Export of mature mRNAs from the nucleus to the cytoplasm is a highly regulated process incorporating quality assurance checks. The researchers prepared RNA from cytosolic and nuclear cell fractions for comparison. In knockdown cells following TNF-á induction, the nuclear fractions had much larger amounts of A20 and IêBá than the cytosolic fractions, suggesting accumulation in the nucleus.

The impact observed on the synthesis and export of A20 and IêBá in DSIF knockdown cells was striking. A20 and IêBá are also responsible for regulating other cell signalling processes and it is likely that the effects on associated signalling processes contribute to the overall impact of DSIF knockdown.

As the authors point out, diminished DSIF activity could contribute to pathological states in which NF-êB becomes constitutively active, such as inflammatory and autoimmune diseases, neurological disorders, and cancer. Further work on DSIF activity could help develop new approaches to treating these diseases.

Acknowledgments
These results were conducted as part of the JST's PRESTO project, "Epigenetic control and biological functions" (Research Supervisor: Dr. Tsunehiro Mukai, professor emeritus, Saga University).
Further information:
Yukiko Tokida
Center for Public Information, Tokyo Institute of Technology
2-12-1, Ookayama, Meguro-ku, Tokyo 152-8550, Japan
E-mail: kouhou@jim.titech.ac.jp
URL: http://www.titech.ac.jp/english/
Tel: +81-3-5734-2975
Fax: +81-3-5734-3661

About Tokyo Institute of Technology
As one of Japan’s top universities, Tokyo Institute of Technology seeks to contribute to civilization, peace and prosperity in the world, and aims at developing global human capabilities par excellence through pioneering research and education in science and technology, including industrial and social management. To achieve this mission, we have an eye on educating highly moral students to acquire not only scientific expertise but also expertise in the liberal arts, and a balanced knowledge of the social sciences and humanities, all while researching deeply from basics to practice with academic mastery. Through these activities, we wish to contribute to global sustainability of the natural world and the support of human life.
Associated links
http://www.titech.ac.jp/english/
Journal information
Gil Diamant, Liat Amir-Zilberstein, Yuki Yamaguchi, Hiroshi Handa, and Rivka Dikstein, “DSIF restricts NFêB signaling by coordinating elongation with mRNA processing of negative feedback genes” , Cell Reports, 2, (4), pp.722­731, (2012)

DOI: 10.1016/j.celrep.2012.08.041.

Adarsh Sandhu | Research asia research news
Further information:
http://www.titech.ac.jp/english/
http://www.researchsea.com

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>